Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses-Reference-Cited by-同舟云学术

Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses

Published:2016-09-09 Issue:11 Volume:5 Page:e1232219
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Hotz Christian,Treinies Marina,Mottas Ines,Rötzer Laurin C.,Oberson Anne,Spagnuolo Lorenzo,Perdicchio Maurizio,Spinetti Thibaud,Herbst Tina,Bourquin Carole

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1232219

Reference45 articles.

1. Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge

2. Dendritic Cells: Translating Innate to Adaptive Immunity

3. Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15

4. Translating nucleic acid-sensing pathways into therapies

5. Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12-Week Open-Label Trial

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GSDMD is associated with survival in human breast cancer but does not impact anti-tumor immunity in a mouse breast cancer model;Frontiers in Immunology;2024-08-19

2. The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells;European Journal of Pharmacology;2024-03

3. Gender Control of Mouse Embryos by Activation of TLR7/8 on X Sperm via Ligands dsRNA-40 and dsRNA-DR;Molecules;2024-01-04

4. Molecular Masking of Synthetic Immunomodulator Evokes Antitumor Immunity With Reduced Immune Tolerance and Systemic Toxicity by Temporal Activity Recovery and Sustained Stimulation;Advanced Materials;2023-12-14

5. Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies;Cancer Immunology Research;2023-12-07